简
繁
EN
简
繁
EN
HOME
·
first-in-human
Henlius (02696.HK): HLX316 (B7-H3-Targeting Sialidase Fc Fusion Protein) Completes First Patient Dosing in Phase I Trial
Tags:
HENLIUS
02696.HK
first-in-human
2026-05-22
Featured News
Finance
Intraco Limited: Issues SGD and USD Denominated Digital Securities Commercial Papers
Finance
CapitaLand Ascendas REIT Officially Launches S$1.4 Billion Geneo Project to Revitalise Singapore Science Park
Research
Large Model Concept Stocks Volatility: Intensive Product Releases and Comprehensive Multi-functional Application Landscape Unfold
ETF
CSOP Hang Seng Index ETF (03037.HK) Rose 1.10%, with the Latest Price at HKD 25.840
ETF
Acceleration in Enterprise-Level AI Application Deployment; Wanjia Hang Seng Internet Technology Industry ETF(159202) Rises 1.26%
ETF
iShares Hang Seng TECH ETF (03067.HK) Rose 1.89%, with the Latest Price at HKD 10.220
ETF
Ping An of China CSI HK Dividend ETF (03070.HK) Rose 0.38%, with the Latest Price at HKD 42.100
ETF
ChinaAMC Hang Seng TECH Index ETF (03088.HK) Rose 1.98%, with the Latest Price at HKD 6.185
ETF
Global X Hang Seng High Dividend Yield ETF (03110.HK) Rose 0.12%, with the Latest Price at HKD 32.360
ETF
ChinaAMC HSI ESG ETF (03403.HK) Rose 0.92%, with the Latest Price at HKD 52.400
Scan QR Code
Download App